Tisotumab vedotin for the treatment of cervical carcinoma.

Abstract

Cervical cancer is one of the most common gynecological malignancies. At present, cytotoxic chemotherapeutic drugs and immunotherapy are the main therapeutic options for recurrent and metastatic cervical cancer. Tisotumab vedotin is an antibody-drug conjugate (ADC) and a potential novel treatment for cervical carcinoma. Tisotumab vedotin targets tissue factor (TF), which is highly expressed on the surface of cervical cancer cells, by delivering the cytotoxic agent monomethyl auristatin E (MMAE) directly into tumor cells. Currently, the U.S. Food and Drug Administration (FDA) has approved tisotumab vedotin for the treatment of adult female patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. This article reviews the results of preclinical studies and clinical trials of tisotumab vedotin. The findings suggest that tisotumab vedotin can induce clinically significant and long-lasting remission with controllable and tolerable safety in the difficult-to-treat group of cervical cancer patients.

• Authors: Xin Song, Ruyi Li, Hongwei Wang, Peng Song, Wenjing Guo, Zhe-Sheng Chen
• Journal: Drugs of today (Barcelona, Spain : 1998) (Drugs Today (Barc)) Vol. 58 Issue 5 Pg. 213-222 (May 2022) ISSN: 1699-3993 [Print] Spain
• PMID: 35535813 (Publication Type: Journal Article, Review)
• Copyright: Copyright 2022 Clarivate.

Chemical References

• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents
• Immunoconjugates
• Oligopeptides
• tisotumab vedotin

Topics

• Adult
• Antibodies, Monoclonal, Humanized (therapeutic use)
• Antineoplastic Agents (therapeutic use)
• Female
• Humans
• Immunoconjugates (therapeutic use)
• Oligopeptides
• Uterine Cervical Neoplasms (drug therapy, pathology)